Texaphyrin oxaliplatin conjugate(The iQ Group Global)

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameTexaphyrin oxaliplatin conjugate(The iQ Group Global)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA synthesis inhibitorsDNA cross linking agents
TargetsDNA
Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsOvarian NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A